Archives
Privately funded healthcare services deadline looming
The deadline for continuing the Competition and Markets Authority (CMA) investigation into the privately funded healthcare services is looming.
The CMA has been looking into whether there’s any anti-competitive arrangements in the sector. If there are, competition may be stifled, and the consumer may be getting hit in the pocket.
When it comes to investigations that involve healthcare, they can often be the most important ones. They say that you can’t put a price on your health, but in reality, big medical companies and pharmaceutical giants literally do just that.
Anti-virus software sector investigation latest
Here’s the latest in the important anti-virus software sector investigation that’s being conducted by the CMA (Competition and Markets Authority).
It’s an important one, especially given how prevalent cybersecurity is these days. There have been so many hacks and attacks in recent times that all organisations – both public and private sector – must invest properly to ensure that they’re defended.
But are service providers in the sector offering their vital line of defence in terms that are deemed as fair, and in the spirit of healthy competition? That’s essentially what the CMA wants to find out.
CMA launch review into unarranged overdraft alerts
Following the Retail Banking Market Investigation Order 2017, the Competition and Markets Authority (CMA) has announced a review into the unarranged overdraft alerts aspect of the order.
The decision for a review to be carried out by the CMA was outlined at the start of July. It involves potential changes that may come about as a result of the FCA (Financial Conduct Authority) becoming involved with new rules set for the end of the year.
With banks having made significant amounts of money for a number of years from fees charged for overdrafts, this continues to be an important matter for regulators to keep an eye on.
Privately funded healthcare competition investigation
The privately funded healthcare competition investigation was initiated by the CMA (Competition and Markets Authority) last month.
At this stage, it’s only an initial investigation, and as the CMA often confirm, there are no assumptions to be made at this moment in time. What we do know is that a decision as to whether the investigation will continue or not is set to be made in the next couple of months.
As more and more services are outsourced to the private sector in relation to healthcare, this could be a significant investigation.
Supply of precast concrete drainage investigation update
Here’s the latest in the investigation into the suspected cartel arrangements in the supply of precast concrete drainage sector.
The investigation being conducted by the CMA (Competition and Markets Authority) was launched way back in 2016. Since then, a number of steps have been taken, and admissions of participating in cartel behaviour have been made at the end of 2018.
The final penalty amounts have yet to be concluded and issued, but based on the most recent update from the CMA, we expect to be seeing more updates soon.
The ongoing Viagogo court case between the Competition and Markets Authority (CMA) and the secondary ticketing website is about to step up.
The CMA are reportedly moving ahead with contempt of court proceedings on the basis that they say Viagogo is still failing to adhere to a court order obtained earlier this year.
This is huge news, and it’s alarming to hear that the CMA considers that the ticketing resellers are still failing to comply with a court order. Following a market sector review, a number of firms changed their behaviours, but it appears that Viagogo isn’t fully complying.
CMA anti-virus software investigation latest
The CMA anti-virus software investigation was launched back in December 2018, and the consumer regulator has been looking into whether renewal practices are legally compliant.
This investigation was a part of the wider loyalty penalty super complaint. With both personal and business reliance on anti-virus software prevalent, this is a huge market sector where there’s a need to ensure that consumer law is always being adhered to.
In the most recent update, the CMA (Competition and Markets Authority) has provided a little more insight into what they’re focusing on as part of their market review.
Investment consultants investigation concludes
The Competition and Markets Authority (CMA) has issued a final order in the investment consultants investigation that’s been ongoing since 2017.
The final step in the reforms that the CMA has been pushing forward has been put in place with the aim or improving the sector on the whole. Clearer information is now to be provided for customers who can enjoy better knowledge about the value for money they can get. There are also greater incentives for pension scheme trustees to shop around for better deals.
The aim, of course, is to ensure that consumers can get best value for their money. The order made is legally-binding, and is designed to ensure that pension trustees make better decisions for the retirement assets they manage.
Groundworks supplier investigation: the latest
There’s an ongoing groundworks supplier investigation being conducted by the Competition and Markets Authority (CMA), so here’s the latest.
The investigation surrounds suspicions of anti-competitive behaviour in the sector for the supply of groundworks products to the construction industry. The CMA’s investigation is looking into whether any of the key suppliers in the market are breaching important competition laws. If they are found to be acting unethically, they could face substantial fines.
The investigation has been going on for some time now, and a great deal of evidence has been collected and reviewed so far.
Provisional finding in the pharmaceuticals competition investigation
There has been a provisional finding in the pharmaceuticals competition investigation by the Competition and Markets Authority (CMA) who have been looking into companies for quite some time.
It has been alleged that anti-competitive agreements are in place between four firms in the sector, and the calculated costs to the NHS is terrifying. If the provisional finding is formalised, huge fines could be issued to the alleged offenders involved in the investigation.
The costs of anti-competitive arrangements in the pharmaceutical industry often fall on the NHS, and therefore on the taxpayer, which is why these kinds of investigations are incredibly important.